PAVM Stock Overview
Focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 4 more risks
PAVmed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$4.87 |
| 52 Week Low | US$0.60 |
| Beta | 0.69 |
| 11 Month Change | -5.99% |
| 3 Month Change | 49.08% |
| 1 Year Change | -68.34% |
| 33 Year Change | -98.30% |
| 5 Year Change | -92.05% |
| Change since IPO | -99.48% |
Recent News & Updates
Recent updates
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?
Jan 29
Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?
Aug 17PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
Aug 16PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress
Jul 05Start Accumulating PAVmed
Dec 24We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth
Sep 02PAVmed: Long Term Investment Case Remains Despite Weak Q2
Aug 23PAVmed: A True Game-Changer For Medical Device Innovation
Jun 14PAVmed forms digital health company, Veris Health
Jun 02PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device
May 26PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans
May 19PAVmed drops 14% on launch of $13.4M direct offering
Jan 06PAVmed closes additional direct offering of common stock
Dec 22Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?
Dec 16PAVmed offers stock for $8.9M
Dec 11PAVmed EPS beats by $0.02
Nov 17There Is Progress At PAVmed, But More Patience Is Required
Oct 30Shareholder Returns
| PAVM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | -1.2% |
| 1Y | -68.3% | 20.9% | 30.4% |
Return vs Industry: PAVM underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: PAVM underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| PAVM volatility | |
|---|---|
| PAVM Average Weekly Movement | 19.8% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PAVM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PAVM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 107 | Lishan Aklog | www.pavmed.com |
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform.
PAVmed Inc. Fundamentals Summary
| PAVM fundamental statistics | |
|---|---|
| Market cap | US$10.61m |
| Earnings (TTM) | US$14.72m |
| Revenue (TTM) | US$4.03m |
0.7x
P/E Ratio2.6x
P/S RatioIs PAVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAVM income statement (TTM) | |
|---|---|
| Revenue | US$4.03m |
| Cost of Revenue | US$6.40m |
| Gross Profit | -US$2.37m |
| Other Expenses | -US$17.08m |
| Earnings | US$14.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.41 |
| Gross Margin | -58.73% |
| Net Profit Margin | 364.77% |
| Debt/Equity Ratio | -341.4% |
How did PAVM perform over the long term?
See historical performance and comparison